

ERRATUM

Open Access



Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection

M. P. Snee¹, L. McParland², F. Collinson², C. M. Lowe², A. Striha², D. R. Baldwin³, B. Naidu⁴, D. Sebag-Montefiore^{1,6}, W. M. Gregory², J. Bestall⁵, J. Hewison⁵, S. Hinsley² and K. N. Franks^{1*}

Erratum

After publication of the original article [1], it came to the authors' attention that a source of funding had been inadvertently omitted from the Acknowledgements section; support from Yorkshire Cancer Research should have mentioned originally.

Author details

¹Department of Clinical Oncology, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK. ²Clinical Trials Research Unit (CTRU), Leeds Institute of Clinical Trials Research, University of Leeds, 71-75 Clarendon Road, Leeds LS2 9PH, UK. ³Respiratory Medicine Unit, David Evans Research Centre, Nottingham University Hospitals and University of Nottingham, Hucknall Rd, Nottingham NG5 1PB, UK. ⁴School of Clinical and Experimental Medicine, University of Birmingham, BirminghamEdgbaston B15 2TTUK. ⁵Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, 101 Clarendon Rd, Leeds LS2 9LJ, UK. ⁶Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, Beckett Street, Leeds LS9 7TF, UK.

Published online: 12 September 2016

Reference

1. Snee MP, McParland L, Collinson F, Lowe CM, Striha A, Baldwin DR, et al. The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection. *Pilot Feasibility Studies*. 2016;2:5. doi:10.1186/s40814-016-0046-2.

* Correspondence: kevin.franks@nhs.net

¹Department of Clinical Oncology, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Beckett Street, Leeds LS9 7TF, UK